Biofidelity is a rapidly-growing commercial-stage genomic technology company dedicated to bringing the benefits of precision medicine to patients around the world. ASPYRE®, the first application of our novel molecular biology technology platform, makes genomic analysis simpler, faster, and more efficient. With the ability to harness existing instrumentation commonplace in laboratories worldwide, ASPYRE provides straightforward, cost-effective access to the vital information needed for accurate targeting and monitoring of cancer treatment. Founded in 2019, Biofidelity is comprised of scientists, engineers, physicians and commercial experts dedicated to making genomics globally accessible. For more information, please visit biofidelity.com and connect with us on LinkedIn and Twitter.